A post hoc pooled analysis of the LIBERTY-PN PRIME and PRIME2 trials examined additional treatment outcomes with dupilumab in patients with prurigo nodularis (PN) who did not attain the stringent composite endpoint of a ≥4-point reduction in Worst Itch Numeric Rating Scale (WI-NRS) score together with an Investigator’s Global Assessment for PN-Stage (IGA PN-S) score of 0/1 at week 24. The analysis included 99 patients receiving dupilumab and 144 receiving placebo.
At week 24, clinically meaningful improvements were observed across multiple patient- and clinician-reported measures in the dupilumab group. A ≥9-point reduction in Dermatology Life Quality Index (DLQI) score was reported in 61.1% of patients, while 55.8% achieved a Patient Global Impression of Severity (PGIS) rating of “none” or “mild.” In addition, 53.7% demonstrated ≥75% healed lesions according to the Prurigo Activity…
